NCT01098565

Brief Summary

The purpose of this study is to provide proof-of-concept that the test product can perform as intended in an intra-operative setting and the responses to the test product are perceivable in a person. The study will also compare results of the test product to the commercially-available product. Hypothesis: the test product will elicit successful test results in over 90% of test product.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
6

participants targeted

Target at below P25 for phase_1

Timeline
Completed

Started Apr 2010

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 25, 2010

Completed
7 days until next milestone

Study Start

First participant enrolled

April 1, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 2, 2010

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2011

Completed
Last Updated

August 2, 2013

Status Verified

August 1, 2013

Enrollment Period

1.6 years

First QC Date

March 25, 2010

Last Update Submit

August 1, 2013

Conditions

Outcome Measures

Primary Outcomes (1)

  • The HFR0001 device can elicit distinct intra-operative responses in subject symptoms.

    Responses include testing parameters and symptom effects

    9 months

Secondary Outcomes (1)

  • Adverse events that occur with the acute implantation and intra-operative testing of the study device.

    9 months.

Study Arms (1)

Study device arm

EXPERIMENTAL
Device: Study device HFR0001

Interventions

Study device will be tested for up to 2 hours prior to chronic device implant.

Study device arm

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject is indicated for Activa® DBS implant for the treatment of Parkinson's disease and scheduled for surgery at the study site.
  • Subject is willing to sign the informed consent to participate in the study.
  • Subject is 18 years of age or older.
  • Subject is a male or non-pregnant female.
  • Subject has no factors that would put the subject at an additional risk for intra-operative or postoperative bleeding. This includes underlying disorders of the coagulation cascade (eg, hemophilia), disorders that affect platelet count or function (eg, Von Willebrand's disease), as well as administration of any anti-platelet or anti-coagulant medication in the 7 days prior to surgery, or any history of anticoagulant or aspirin use, that in the view of the neurosurgeon or neurologist would place the subject at an increased risk for intra-operative or postoperative bleeding.

You may not qualify if:

  • Subject is indicated for DBS for treating a disorder other than Parkinson's disease.
  • Subject has any medical contraindications to undergoing DBS surgery, (eg, infection, coagulopathy, or significant cardiac or other medical risk factors for surgery).
  • Subject has a history of hemorrhagic stroke.
  • Subject has a history of a neurosurgical ablation procedure.
  • Subject is currently enrolled in or plans to enroll in any concurrent study that may confound the results of this study, as determined by the investigator or Medtronic.
  • Subject has a diagnosis of acute myocardial infarction or cardiac arrest less than or equal to 6 months prior to the screening testing.
  • Subject has a history of a seizure disorder
  • Subject requires short surgery time due to general health issues, as determined by the investigator.
  • Subject is a woman who is pregnant or planning to become pregnant, or a woman of child-bearing potential, who is not using a medically-acceptable method of birth control. Women of child-bearing potential must undergo a pregnancy test, with a clear negative result, no more than 7 days prior to the investigational procedure visit.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Christian Albrechts University of Kiel

Kiel, D-24105, Germany

Location

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Study Officials

  • H. Maximilian Mehdorn, MD, PhD

    University Clinics Kiel, Department of Neurosurgery

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 25, 2010

First Posted

April 2, 2010

Study Start

April 1, 2010

Primary Completion

November 1, 2011

Study Completion

November 1, 2011

Last Updated

August 2, 2013

Record last verified: 2013-08

Locations